

Last Updated January 13, 2007  
Cardiac Pharmacology Bibliography Update  
Copyright © 2007 National Healthcare Innovations  
Carol A. White, RN, MS, GNPC, ANPC, CLNC

- Afsarmanesh, N., Horwich, T. B., & Fonarow, G. C. (2006). Total cholesterol levels and mortality risk in nonischemic systolic heart failure. *American Heart Journal*, 152(6), 1077-1083.
- Aksnes, T. A., Flaa, A., Strand, A., & Kjeldsen, S. E. (2007). Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. *Journal of Hypertension*, 25(1), 15-23.
- Al-Hesayen, A., Floras, J. S., & Parker, J. D. (2006). The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. *European Journal of Heart Failure*, 8(8), 864-868.
- American Diabetes Association. (2006). Clinical practice recommendations – standards of medical care in diabetes. *Diabetes Care*, 29 (suppl.1), S4-S42.
- Appel, L. J. Brands, M. W., Daniels, S. R., et al. (2006). Dietary approaches to prevent and treat hypertension. A scientific statement from the American Heart Association. *Hypertension*, 47, 296-308.
- Baer, A. A., & Wortmann, R. L. (2007). Myotoxicity associated with lipid-lowering drugs. Systemic disorders with rheumatic manifestations. *Current opinion in Rheumatology*, 19(1), 67-73.
- Bressler, R. (2006). Grapefruit juice and prescription drug interactions. *Geriatrics*, 61 (11), 12-18.

- Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. *Drug Metab Dispos*, 27(8), 866-871.
- Deedwania, P., Bator, P., Carmena R., et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the treating to new targets study. *Lancet*, 368, 1-10.
- Fogari, R., & Zoppi, A. (2004). Effect of antihypertensive agents on quality of life in the elderly. *Drugs Aging*, 21(6), 377-393.
- Ford, E. S. (2004). Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. *Diabetes Care*, 28, 1769-1778.
- Forrester, J. S., & Shah, P. K. (2006). Emerging strategies for increasing high-density lipoprotein. *The American Journal of Cardiology*, 98(11), 1542-1549.
- Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., et al. (2003). Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. *Clin Pharmacol Ther* 74(2), 121-129.
- Guo, X., Feng, J., & Guo, H. (2006). The predictive value of the bedside troponin T test for patients with acute chest pain. *Clinical Cardiology*, 11(3), 298-301.
- LaRosa, J. C., Grundy, S. M., Waters, D. D., et al. (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*, 352, 13-22.
- Leaf, A., Kang, J. X., Xiao, Y. F., & Billman, G. E. (2003). Clinical prevention of sudden cardiac death by n-3

- polyunsaturated fatty acid and mechanism of prevention of arrhythmias by n-3 fish oils. *Circulation*, 107, 2646-2652.
- Merz, C. N., Buse, J. B., Tuncer, D., & Twillman, G. B. (2002). Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. *Journal of the American College of Cardiology*, 40 (1), 1877-1881.
- Newton, J. D., & Squire, I. B. (2006). Glucose and hemoglobin in the assessment of prognosis after first hospitalization for heart failure. *Heart*, 92, 1441-1446.
- Niskanen, L., Hedner, T., Hansson, L., Lanke, J., & Niklason, A. (2001). Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker based treatment regimen: A sub analysis of the Captopril Prevention Project. *Diabetes Care* 24(12), 2091-2096.
- Olshansky, B., Sami, M., Rubin, A., et al. and NHLBI AFFIRM Investigators. (2005). Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. *Am J Cardiol* 95(3), 404-405.
- Ott, M. C., Khor, A., Leventhal, J. P., et al. (2003). Pulmonary toxicity in patients receiving low-dose amiodarone. *Chest* 123(2), 646-651.
- Papadopoulos, D. P. & Papademetriou, V. (2006). Resistant hypertension: diagnosis and management. *Journal of the Cardiovascular Pharmacol Ther*, 11, 113-118.
- Pedersen, T. R., Faergeman, O., Kastelein, J. J., et al. (2005). Incremental decrease in end points through aggressive lipid lowering (IDEAL) Study Group. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after

- myocardial infarction: The IDEAL study: A randomized controlled trial. *JAMA* 294, 2437-2445.
- Poon, I., & Lal, L. (2006). An overview of orthostatic hypotension. *US Pharm*, 12, HS32-HS41.
- Ray, K. K. Bach, R. G., Cannon, C. P. et al. (2006). PROVE-IT TIMI 22 Investigators. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. *Eur Heart J*, 27, 2310-2316.
- Regularly ask patients if they take their heart, diabetes medications. (2006). *Arch Intern. Med.* 166(17), 1836-1841, 1842-1847.
- Shepherd, J., Barter, P., Carmena R., et al. (2006). Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. *Diabetes Care*, 29, 1220-1226.
- Siirila-Waris, K., Lassus, J., Melin, J., Peuhkurinen, K., Nieminen, M. S., & Harjola, V. for the FINN-AKVA study group. (2006). Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. *European Heart Journal*, 27(24), 3011-3017.
- Taylor E .N., Hu, F. B., & Curhan, C. G. (2006). Antihypertensive medications and the risk of incident type 2 diabetes. *Diabetes Care*, 29(5), 1065-1070.
- Tsioufis, C., Thomopoulos, K., Dimitriadis, K., et al. (2007). The incremental effect of obstructive sleep apnea syndrome on arterial stiffness in newly diagnosed essential hypertensive subjects. *Journal of Hypertension*, 25(1), 141-146.

- Vidt, D. G. (2005). Clinical trials report: Treatment of hypertension in various racial subgroups. *Curr Hypertens Rep*, 7, 312-313.
- Walker, K. J., Bond, A. E., Beckstrand, R. L., & Williams, M. (2006). Omega-3 fatty acid consumption in the reduction of sudden cardiac death: A critical appraisal. *The American Journal for Nurse Practitioners*, 10(11/12), 11-24.
- Wang, T., Charette, S., & Sith, M. I. (2006). An unintended consequence: Fatal amiodarone pulmonary toxicity in an older woman. *JAMDA*, 7(8), 510-513.
- Wannamethee, S. G. Shaper, A. G., & Whincup, P. H. (2006). Modifiable lifestyle factors and the metabolic syndrome in older men: Effects of lifestyle changes. *Journal of the American Geriatric Society*, 54(12), 1909-1914.
- Weinberg, A., Altman, J., & Pals, J. (2006). Quality improvement case study: Warfarin sodium interactions. *JAMDA*, 7(5), 315-318.
- Wong, M. D., Shapiro, M. F., Boscardin, W. J., et al. (2002). Contribution of major disease to disparities in mortality. *N Engl J Med* (2002). 347, 1585-1592.